Pacific Biosciences
(PACB)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 99,868 | 76,946 | 180,211 | 385,948 | 209,587 |
| Marketable Securities | 410,276 | 485,268 | 451,505 | 382,141 | 620,575 |
| Receivables | 32,433 | 30,323 | 36,615 | 30,486 | 24,034 |
| Inventories | 68,594 | 67,343 | 56,676 | 68,256 | 67,608 |
| TOTAL | $628,139 | $677,024 | $742,047 | $882,297 | $935,552 |
| Non-Current Assets | |||||
| PPE Net | 34,910 | 37,291 | 36,432 | 40,340 | 40,317 |
| Intangibles | 812,339 | 912,392 | 919,245 | 925,681 | 819,753 |
| Other Non-Current Assets | 34,103 | 43,213 | 48,289 | 50,036 | 52,009 |
| TOTAL | $881,352 | $992,896 | $1,003,966 | $1,016,057 | $912,079 |
| Total Assets | $1,509,491 | $1,669,920 | $1,746,013 | $1,898,354 | $1,847,631 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 17,488 | 21,006 | 15,062 | 16,106 | 16,512 |
| Accrued Expenses | 22,456 | 21,991 | 45,708 | 34,660 | 27,010 |
| Other current liabilities | 6,747 | 2,836 | 8,326 | 101,363 | 193,661 |
| TOTAL | $78,390 | $72,951 | $95,029 | $183,961 | $271,409 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 19,212 | 17,346 | 16,342 | 22,372 | 24,983 |
| Other Non-Current Liabilities | 932,695 | 941,825 | 944,150 | 945,597 | 929,231 |
| TOTAL | $938,401 | $947,952 | $949,680 | $950,650 | $934,223 |
| Total Liabilities | $1,016,791 | $1,020,903 | $1,044,709 | $1,134,611 | $1,205,632 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 272,529 | 272,356 | 267,952 | 267,444 | 250,558 |
| Common Shares | 272 | 272 | 268 | 258 | 250 |
| Retained earnings | -2,090,572 | -1,917,253 | -1,839,075 | -1,757,057 | -1,690,188 |
| Other shareholders' equity | -523 | -306 | 219 | -1,840 | -2,686 |
| TOTAL | $492,700 | $649,017 | $701,304 | $763,743 | $641,999 |
| Total Liabilities And Equity | $1,509,491 | $1,669,920 | $1,746,013 | $1,898,354 | $1,847,631 |